Literature DB >> 1683777

Multidrug resistance from the clinical point of view.

C K van Kalken1, H M Pinedo, G Giaccone.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1683777     DOI： 10.1016/0277-5379(91)90036-d

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  10 in total

1.  Current status and future directions of research on multidrug resistance. The impact of contemporary biotechnology.

Authors:  G H Mickisch
Journal:  Urol Res       Date:  1993-03

2.  Multidrug resistance gene (P-glycoprotein) expression in the human fetus.

Authors:  C K van Kalken; G Giaccone; P van der Valk; C M Kuiper; M M Hadisaputro; S A Bosma; R J Scheper; C J Meijer; H M Pinedo
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

3.  Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.

Authors:  C Etiévant; O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

Authors:  O Pauwels; R Kiss
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.

Authors:  M Mariani; L Capolongo; A Suarato; A Bargiotti; N Mongelli; M Grandi; W T Beck
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.

Authors:  R Lacave; F Coulet; S Ricci; E Touboul; A Flahault; J G Rateau; D Cesari; J P Lefranc; J F Bernaudin
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.

Authors:  S C Linn; A H Honkoop; K Hoekman; P van der Valk; H M Pinedo; G Giaccone
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

8.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Authors:  S Dhar; P Nygren; K Csoka; J Botling; K Nilsson; R Larsson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

9.  Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.

Authors:  H Fridborg; B Jonsson; P Nygren; K Csoka; K Nilsson; G Oberg; J Kristensen; J Bergh; B Tholander; L Olsen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

10.  Aptamer-functionalized Hybrid Nanoparticles to Enhance the Delivery of Doxorubicin into Breast Cancer Cells by Silencing P-glycoprotein.

Authors:  Sruti Chandra; Hoang Michael Nguyen; Kylar Wiltz; Nicholas Hall; Shanzay Chaudhry; George Olverson; Tarun Mandal; Srikanta Dash; Anup Kundu
Journal:  J Cancer Treatment Diagn       Date:  2020
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.